†Response (≥50% decrease in depressive severity) and remission (as defined by authors of individual trials) were measured using HRSD unless indicated otherwise.
Disease activity throughout the trial was measured using disease activity indices and monitoring blood.
Again by way of explanation, quality of life outcomes for the sciatica trial were measured using the SF36 instrument, translated to the SF-6D and its associated utilities.
In all trials, PCT was measured using a rapid, sensitive assay with a functional assay sensitivity of 0.06 μg/L (KRYPTOR PCT; B∙R∙A∙H∙M∙S, Hennigsdorf, Germany) and an assay time of less than 20 minutes.
Cancer clinical trial understanding was measured using a revised Index of Clinical Trial Understanding (ICTU) [ 17].
In the recent analysis of the ICON7 trial, QoL was measured using the EORTC QLQ C30 and OV28.
As part of the DENSE trial, mammographic density was measured using a fully-automated volumetric method.
In the three nalmefene clinical trials, quality of life was measured using EQ-5D at baseline, 3 and 6 months, and additionally at 12 months for SENSE.
Peak grip strength, defined as the highest value of three trials for each hand, was measured using a hand dynamometer ("GRIPPIT", AB Detektor, Gothenburg, Sweden) and reported in Newtons (N) [ 35, 36].
In Van den Berghe and colleagues' original trial, blood glucose concentration was measured using a blood gas analyzer, a method that has been shown to be accurate [ 2].
